STEM CELLS -- STEM CELLS -- CONTENTS -- PREFACE -- ADULT NEURAL STEM CELLS:APROMISINGCANDIDATE FOR REGENERATIVE THERAPY IN THECNS -- ABSTRACT -- 1. INTRODUCTION -- 2. FETAL NEURONAL CELLS -- 3. PARACRINE SYSTEMS -- 4. STEM CELLS -- 4.1. Embryonic Stem Cells -- 4.2. Cloned Embryonic Stem Cells -- 4.3. Neural Stem Cells -- 5. CONCLUSION -- ACKNOWLEDGMENTS -- REFERENCES -- NEURAL PROGENITOR AND STEM CELLS IN THEADULT CENTRAL NERVOUS SYSTEM -- ABSTRACT -- 1. INTRODUCTION -- 2. NEUROGENESIS OCCURS IN THE ADULT MAMMALIAN BRAIN -- 3. NEURAL STEM AND PROGENITOR CELLSRESIDE IN THE ADULT CNS -- 4. ORIGIN OF NEWLY GENERATED NEURONALCELLS IN THE ADULT BRAIN -- 5. NEUROGENESIS AND CNS PATHOPHYSIOLOGY -- 6. CELLULAR THERAPY -- 7. CONCLUSION -- ACKNOWLEDGMENTS -- REFERENCES -- NEUROGENESIS IN THE ADULTCENTRAL NERVOUS SYSTEM -- ABSTRACT -- 1. INTRODUCTION -- 2. NEUROGENESIS IN THE ADULT BRAIN -- 3. NEURAL PROGENITOR AND STEM CELLS FROM THE ADULT BRAIN -- 4. NEURAL PROGENITOR AND STEM CELLS IN THE ADULT BRAIN -- 5. A DEVELOPMENTAL PROCESS -- 6. REDEFINING CNS PHYSIOPATHOLOGY -- 7. CELLULAR THERAPY IN THE ADULT CNS -- 8. CONCLUDING REMARKS -- ACKNOWLEDGEMENTS -- REFERENCES -- BRDUIMMUNOHISTOCHEMISTRY FORSTUDYING ADULT NEUROGENESIS:PARADIGMS, PITFALLS, LIMITATIONSAND VALIDATION -- ABSTRACT -- 1. INTRODUCTION -- 2. ADULT NEUROGENESIS -- 2.1. In the Mammalian Brain -- 2.2. Temporal and Spatial Expression of Markers of Newly GeneratedNeuronal Cells -- 2.3. Quantitative Studies -- 2.4. Modulation of Neurogenesis -- 3. STRATEGIES FOR STUDYING ADULT NEUROGENESIS -- 3. 1. BrdU Labeling -- 3.2. Cell Cycle Markers -- 3.3. Other Strategies -- 4. ASSESSMENT OF BRDU LABELING FOR STUDYING CELLPROLIFERATION AND ADULT NEUROGENESIS -- 4.1. BrdU a Toxic Substance -- 4.2. Saturating Doses of BrdU -- 4.3. DNA Repair -- 4.4. Gene Regulation -- 4.5. Abortive Cell Cycle Re-Entry.

4.6. Gene Duplication -- 4.7. BrdU Immunohistochemistry and Multiple Labeling -- 4.8. BrdU Transfer -- 5. CONCLUDING REMARKS -- ACKNOWLEDGMENTS -- REFERENCES -- DERIVATION OF EMBRYONIC STEMCELLS FOR CELLULAR THERAPY:CHALLENGES AND NEW STRATEGIES -- ABSTRACT -- 1. INTRODUCTION -- 2. FROM ES CELLS TO THERAPY: THE CHALLENGES AHEAD -- 3. OVERCOMING THE ETHICAL AND POLITICAL CHALLENGES:ALTERNATIVE PROTOCOLS TO DERIVE ES CELLS -- 4. CONCLUSION -- NOTE IN ADDENDUM -- ACKNOWLEDGMENTS -- REFERENCES -- OTI-010 OSIRIS THERAPEUTICS/JCRPHARMACEUTICALS -- ABSTRACT -- 1. INTRODUCTION -- 2. SYNTHESIS AND SAR -- 3. PRECLINICAL DEVELOPMENT -- 3.1. In vitro -- 3.2. In vivo -- 4.METABOLISM AND PHARMACOKINETICS -- TOXICITY -- 6. CLINICAL DEVELOPMENT -- 6.1. GVHD -- 6.2. Transplantation in Cancer Patients -- 6.3. Crohn's Disease -- 7. SIDE EFFECTS AND CONTRAINDICATIONS -- 8. PATENT SUMMARY -- 9. CURRENT OPINION -- 10. LICENSING -- 11. DEVELOPMENT HISTORY -- 12. LITERATURE CLASSIFICATIONS -- 13. ASSOCIATED PATENT -- ACKNOWLEDGMENTS -- REFERENCES -- ADULT NEURAL STEM CELLS, NEUROGENIC NICHESAND CELLULAR THERAPY -- ABSTRACT -- 1. INTRODUCTION -- 2. ADULT NEUROGENESIS AND NSCS -- 3. NEUROGENIC NICHES -- 4. BROADER POTENTIAL OF ADULT STEM CELLS -- 5. CELLULAR THERAPY -- 6. CONCLUSION -- ACKNOWLEDGMENTS -- REFERENCES -- THE THERAPEUTIC POTENTIAL OF ADULTNEURAL STEM CELLS -- ABSTRACT -- 1. INTRODUCTION -- 2. ADULT NEUROGENESIS AND NEURAL STEM CELLS -- 3. PHYSIOLOGY OF NEWLY GENERATED NEURONALCELLS IN THE ADULT BRAIN -- 4. ADULT-DERIVED NEURAL PROGENITOR AND STEM CELLS -- 5. CELL-BASED THERAPIES FOR THE TREATMENTOF CNS DISEASE AND INJURY -- 5.1. Stimulation of Endogenous Neural Progenitor Cells -- 5.2. Cell Transplantation -- 6. CONCLUSION -- AUTHOR'S NOTE -- ACKNOWLEDGMENTS -- REFERENCES -- STEM CELLS ENGINEERING FORCELL-BASED THERAPY -- ABSTRACT -- 1. INTRODUCTION.

2. CELL ENGINEERING TO DERIVE ESCS WITHOUTTHE DESTRUCTION OF EMBRYOS -- 3. ADULT NEURAL STEM CELL ENGINEERING -- 4. CONCLUSION -- ACKNOWLEDGMENTS -- REFERENCES -- ADULT NEUROGENESIS PHARMACOLOGY INNEUROLOGICAL DISEASES AND DISORDERS -- KEY ISSUES -- ABSTRACT -- 1. INTRODUCTION -- 2. NEUROGENESIS IN THE ADULT BRAIN -- 3. NEUROGENESIS IN NEUROLOGICAL DISEASES AND DISORDERS -- 3.1. Alzheimer's Disease -- 3.2. Depression -- 3.3. Epilepsy -- 3.4. Huntington's Disease -- 3.5. Parkinson's Disease -- 3.6. Schizophrenia -- 4. NEUROGENESIS AND THE ETIOLOGY OFNEUROLOGICAL DISEASES AND DISORDERS -- 5. PHARMACOLOGY OF ADULT NEUROGENESIS -- 6. DISCUSSION -- 6.1. Limitations and Pitfalls of the Use of BrdU Labeling for StudyingNeurogenesis -- 6.2. Alzheimer's Disease -- 6.3. Depression -- EXPERT COMMENTARY AND FIVE-YEAR VIEW -- FINANCIAL AND COMPETING INTERESTS DISCLOSURE -- ACKNOWLEDGMENTS -- REFERENCES -- ADULT NEUROGENESIS, NEUROINFLAMMATIONAND THERAPEUTIC POTENTIAL OFADULT NEURAL STEM CELLS -- ABSTRACT -- INTRODUCTION -- NEUROINFLAMMATION IN NEUROLOGICAL DISEASES AND INJURIES -- ADULT NEUROGENESIS, NEURAL STEM CELLS AND CELLULARTHERAPY -- ADULT NEUROGENESIS IN NEUROLOGICALDISEASES AND DISORDERS -- NEUROINFLAMMATION IN ADULT NEUROGENESIS -- CONCLUSION AND PERSPECTIVES -- ACKNOWLEDGMENTS -- REFERENCES -- ADULT NEUROGENESIS AND NEUROPLASTICITY -- ABSTRACT -- 1. ADULT NEUROGENESIS AND NEURAL STEM CELLS -- 2. ENHANCED NEUROGENESIS AFTER CEREBRAL STROKE -- 3. ENHANCED NEUROGENESIS AFTER TRAUMATIC BRAIN INJURY -- 4. NEUROREGENERATION -- 5. NEUROPLASTICITY -- 6. CONCLUSION -- ACKNOWLEDGMENTS -- REFERENCES -- HUCNS-SC STEM CELLS -- ABSTRACT -- 1. INTRODUCTION -- 2. SYNTHESIS AND SAR -- 3. PRECLINICAL DEVELOPMENT -- 3.1. Animal NSC -- 3.2. HuCNS-SC -- 4.METABOLISM AND PHARMACOKINETICS -- 5. TOXICITY -- 6. CLINICAL DEVELOPMENT -- 7. SIDE EFFECTS AND CONTRAINDICATIONS.

8. PATENT SUMMARY -- 9. CURRENT OPINION -- 10. LICENSING -- 11. DEVELOPMENT HISTORY -- 12. LITERATURE CLASSIFICATIONS -- 13. ASSOCIATED PATENT -- ACKNOWLEDGMENTS -- REFERENCES -- STEM CELLS FROM NON-VIABLE VERSUSPOST-MORTEM TISSUES -- ACKNOWLEDGMENTS -- REFERENCES -- ADULT NEURAL STEM CELLS FROMPROMISE TO TREATMENT:THE ROAD AHEAD -- ACKNOWLEDGMENTS -- REFERENCES -- INDEX.